Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Interest & Investment Income (2020 - 2023)

Candel Therapeutics' Interest & Investment Income history spans 4 years, with the latest figure at $415000.0 for Q4 2023.

  • For Q4 2023, Interest & Investment Income fell 57.65% year-over-year to $415000.0; the TTM value through Dec 2023 reached $2.1 million, up 70.85%, while the annual FY2024 figure was $1.1 million, 47.81% down from the prior year.
  • Interest & Investment Income for Q4 2023 was $415000.0 at Candel Therapeutics, down from $502000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $980000.0 in Q4 2022 and bottomed at -$175000.0 in Q1 2022.
  • The 4-year median for Interest & Investment Income is $59000.0 (2020), against an average of $238214.3.
  • The largest YoY upside for Interest & Investment Income was 9009.09% in 2022 against a maximum downside of 1358.33% in 2022.
  • A 4-year view of Interest & Investment Income shows it stood at $48000.0 in 2020, then tumbled by 122.92% to -$11000.0 in 2021, then soared by 9009.09% to $980000.0 in 2022, then crashed by 57.65% to $415000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Interest & Investment Income are $415000.0 (Q4 2023), $502000.0 (Q3 2023), and $453000.0 (Q2 2023).